EMERGENT BIOSOLUTIONS INC. (EBS) Current Ratio
- Current ratio · latest quarter: Value 5.42×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.42× | Current assets / current liabilities. $666.00M ÷ $122.80M ≈ 5.42× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 666.00M USD | Assets, Current |
| Current obligations | 122.80M USD | Liabilities, Current |
| Cash and equivalents | 139.70M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 190.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 303.60M USD | Inventory, Net |
| Payables | 50.20M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $666.00M | $122.80M | $139.70M | (m) | $190.00M | $303.60M | $50.20M | (m) | 5.42× |
| 2026-03-31 | $637.60M | $148.70M | $160.30M | (m) | $121.60M | $327.60M | $39.50M | (m) | 4.29× |
| 2025-12-31 | $662.50M | $132.20M | $205.40M | (m) | $84.20M | $343.40M | $55.60M | (m) | 5.01× |
| 2025-09-30 | $786.90M | $136.50M | $245.50M | (m) | $149.50M | $356.30M | $57.40M | (m) | 5.76× |
| 2025-06-30 | $719.50M | $127.10M | $267.30M | (m) | $79.80M | $338.60M | $63.70M | (m) | 5.66× |
| 2025-03-31 | $706.80M | $111.90M | $149.10M | (m) | $203.70M | $314.00M | $58.10M | (m) | 6.32× |
| 2024-12-31 | $598.70M | $162.40M | $99.50M | (m) | $154.50M | $311.70M | $60.90M | (m) | 3.69× |
| 2024-09-30 | $661.40M | $229.90M | $149.90M | (m) | $121.30M | $322.70M | $82.10M | $800.00K | 2.88× |
| 2024-06-30 | $654.50M | $619.70M | $69.70M | (m) | $196.30M | $317.50M | $95.90M | $415.20M | 1.06× |
| 2024-03-31 | $682.40M | $630.20M | $78.50M | (m) | $233.50M | $333.40M | $100.20M | $459.20M | 1.08× |
| 2023-12-31 | $679.50M | $651.30M | $111.70M | (m) | $191.00M | $328.90M | $112.20M | $413.70M | 1.04× |
| 2023-09-30 | $720.80M | $664.00M | $87.80M | (m) | $216.50M | $354.10M | $112.70M | $413.60M | 1.09× |
| 2023-06-30 | $777.70M | $693.20M | $88.60M | (m) | $290.10M | $354.30M | $108.30M | $455.20M | 1.12× |
| 2023-03-31 | $1.22B | $1.22B | $430.20M | (m) | $155.90M | $367.90M | $124.20M | $950.70M | 1.00× |
| 2022-12-31 | $1.21B | $1.23B | $642.60M | (m) | $159.20M | $350.70M | $103.50M | $957.30M | 0.98× |
| 2022-09-30 | $1.10B | $264.40M | $240.90M | (m) | $189.20M | $528.20M | $101.00M | (m) | 4.15× |
| 2022-06-30 | $1.08B | $276.70M | $358.10M | (m) | $175.00M | $425.50M | $106.20M | $31.60M | 3.92× |
| 2022-03-31 | $1.10B | $249.20M | $435.80M | (m) | $181.80M | $400.70M | $107.30M | $31.60M | 4.42× |
| 2021-12-31 | $1.27B | $374.00M | $576.10M | (m) | $278.90M | $344.50M | $128.90M | $31.60M | 3.40× |
| 2021-09-30 | $1.11B | $365.40M | $403.80M | (m) | $254.60M | $364.60M | $135.20M | $31.60M | 3.04× |
| 2021-06-30 | $1.16B | $377.80M | $447.50M | (m) | $261.90M | $386.40M | $151.80M | $28.80M | 3.08× |
| 2021-03-31 | $1.18B | $370.20M | $547.80M | (m) | $184.40M | $406.50M | $142.20M | $26.00M | 3.19× |
| 2020-12-31 | $1.20B | $384.50M | $621.30M | (m) | $230.90M | $307.00M | $136.10M | $33.80M | 3.11× |
| 2020-09-30 | $958.80M | $299.30M | $415.00M | (m) | $196.10M | $270.10M | $102.80M | $30.90M | 3.20× |
| 2020-06-30 | $795.90M | $293.70M | $268.80M | (m) | $258.60M | $236.20M | $84.80M | $29.10M | 2.71× |
| 2020-03-31 | $626.60M | $207.10M | $181.50M | (m) | $162.50M | $248.10M | $84.20M | $26.30M | 3.03× |
| 2019-12-31 | $686.20M | $216.30M | $167.80M | (m) | $270.70M | $222.50M | $94.80M | $12.90M | 3.17× |
| 2019-09-30 | $700.00M | $275.30M | $139.20M | (m) | $281.20M | $230.20M | $91.30M | $10.10M | 2.54× |
| 2019-06-30 | $692.70M | $301.20M | $177.40M | (m) | $218.10M | $232.00M | $124.50M | $10.10M | 2.30× |
| 2019-03-31 | $528.50M | $248.40M | $137.20M | (m) | $121.50M | $211.00M | $78.60M | $10.10M | 2.13× |
| 2018-12-31 | $620.80M | $200.40M | $112.20M | (m) | $262.50M | $205.80M | $80.70M | $10.10M | 3.10× |
| 2018-09-30 | $563.15M | $102.01M | $339.36M | (m) | $76.95M | $125.75M | $38.87M | (m) | 5.52× |
| 2018-06-30 | $541.31M | $96.81M | $190.24M | (m) | $189.49M | $139.37M | $41.63M | (m) | 5.59× |
| 2018-03-31 | $476.65M | $86.87M | $163.61M | (m) | $122.09M | $155.20M | $46.22M | (m) | 5.49× |
| 2017-12-31 | $485.40M | $100.10M | $178.30M | (m) | $143.70M | $142.80M | $41.80M | $0.00 | 4.85× |
| 2017-09-30 | $556.03M | $75.43M | $340.99M | (m) | $129.36M | $68.89M | $30.11M | (m) | 7.37× |
| 2017-06-30 | $509.74M | $72.93M | $315.63M | (m) | $102.51M | $70.53M | $29.60M | (m) | 6.99× |
| 2017-03-31 | $489.17M | $67.71M | $270.17M | (m) | $128.08M | $70.73M | $27.18M | (m) | 7.22× |
| 2016-12-31 | $510.22M | $105.86M | $271.51M | (m) | $138.48M | $74.00M | $34.65M | (m) | 4.82× |
| 2016-09-30 | $480.00M | $110.31M | $298.93M | (m) | $69.63M | $81.16M | $46.34M | (m) | 4.35× |
| 2016-06-30 | $528.05M | $103.86M | $333.39M | (m) | $66.75M | $96.67M | $58.97M | (m) | 5.08× |
| 2016-03-31 | $528.16M | $90.45M | $341.02M | (m) | $69.56M | $88.20M | $45.61M | (m) | 5.84× |
| 2015-12-31 | $537.41M | $99.61M | $312.80M | (m) | $113.91M | $60.89M | $37.97M | (m) | 5.40× |
| 2015-09-30 | $473.49M | $88.72M | $308.72M | (m) | $57.04M | $80.07M | $41.25M | (m) | 5.34× |
| 2015-06-30 | $435.49M | $86.96M | $214.84M | (m) | $99.72M | $84.71M | $41.82M | (m) | 5.01× |
| 2015-03-31 | $405.81M | $80.30M | $216.51M | (m) | $64.06M | $82.13M | $40.58M | (m) | 5.05× |
| 2014-12-31 | $432.18M | $92.94M | $280.50M | (m) | $58.83M | $65.67M | $40.93M | (m) | 4.65× |
| 2014-09-30 | $383.63M | $81.42M | $242.25M | (m) | $44.11M | $62.53M | $39.35M | (m) | 4.71× |
| 2014-06-30 | $345.45M | $76.43M | $168.13M | (m) | $78.27M | $66.03M | $36.97M | (m) | 4.52× |
| 2014-03-31 | $327.20M | $72.32M | $160.22M | (m) | $62.94M | $71.27M | $36.64M | (m) | 4.52× |
| 2013-12-31 | $273.12M | $56.65M | $179.34M | (m) | $60.59M | $14.64M | $27.52M | (m) | 4.82× |
| 2013-09-30 | $234.01M | $56.63M | $172.56M | (m) | $30.09M | $16.32M | $29.02M | $4.47M | 4.13× |
| 2013-06-30 | $248.16M | $48.78M | $156.24M | (m) | $54.37M | $18.58M | $25.71M | $4.47M | 5.09× |
| 2013-03-31 | $237.08M | $43.54M | $130.24M | (m) | $62.96M | $22.15M | $23.87M | $4.47M | 5.44× |
| 2012-12-31 | $263.35M | $61.91M | $141.67M | (m) | $96.04M | $15.16M | $31.30M | $4.47M | 4.25× |
| 2012-09-30 | $252.94M | $50.57M | $197.90M | $0.00 | $17.09M | $18.25M | $27.35M | $4.15M | 5.00× |
| 2012-06-30 | $243.22M | $44.47M | $161.84M | $0.00 | $46.81M | $16.01M | $23.30M | $4.06M | 5.47× |
| 2012-03-31 | $239.54M | $42.99M | $150.43M | $0.00 | $43.65M | $17.32M | $28.32M | (m) | 5.57× |
| 2011-12-31 | $254.42M | $71.05M | $143.90M | $1.97M | $74.15M | $14.66M | $40.53M | $5.36M | 3.58× |
| 2011-09-30 | $236.76M | $68.93M | $125.35M | $3.50M | $48.99M | $17.98M | $33.90M | $4.92M | 3.43× |
| 2011-06-30 | $223.84M | $72.50M | $122.09M | $5.05M | $47.26M | $17.26M | $32.18M | $10.23M | 3.09× |
| 2010-12-31 | $243.49M | $75.72M | $169.02M | $2.03M | $39.33M | $12.72M | $25.41M | (m) | 3.22× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |